Novel Drug Delivery Systems in the management of CNS Disorders

Novel Drug Delivery Systems in the Management of CNS Disorders offers a comprehensive source of information on delivering drugs to the central nervous system to treat various diseases and conditions. The book covers a wide range of CNS disorders, including epilepsy, Parkinson's, Alzheimer's, Huntington's, multiple sclerosis, schizophrenia, cerebral palsy, autism, ALS, and others.
The book begins by presenting the foundations of drug delivery to the brain and addressing the associated challenges. It then delves into clinical trials and explores the future potential of the presented technologies.
This reference is designed for drug delivery researchers in academia and corporations, providing them with the essential knowledge about overcoming the Brain-Blood Barrier and achieving targeted drug delivery to the central nervous system.

Dr. Pooja A Chawla is working as a Professor, at the University Institute of Pharmaceutical Sciences, Baba Farid University of Health Sciences, Faridkot, Punjab, India. She has 22 years of experience in the research, discovery, and development of biologically active pharmaceuticals. Dr. Chawla holds a PhD degree in Pharmaceutical Sciences with a specialization in Pharmaceutical Chemistry and has published 6 books, 25 book chapters, and more than 150 papers in national/international journals and is serving as a reviewer for international journals of repute. Dr. Pooja is also privileged to serve as guest editor of two reputed journals CNS & Neurological Disorders - Drug Targets IF 2.8 and Current Organic Chemistry IF 2.5) of Bentham Sciences. She has been appointed as Academic editor of PLOS ONE journal IF 3.2 and recently she has been appointed as Assistant editor for Health Sciences Review Journal by Elsevier publishers. She has guided more than 60 postgraduate projects and her research team consists of 6 Masters and 4 Doctoral research scholars. Her area of research interest focuses on the design and synthesis of various heterocyclic moieties including 4-Thiazolidinones, 2,4-Thiazolidiedione, Coumarin, Pyrazolines, Schiff's base derivatives to name a few for the discovery of medicinally important agents as anticonvulsants, antidepressants, anticancer, anti Alzheimer's agents. She is well-versed with method development and validation and guiding research scholars in this field.

Prof Raimar Löbenberg holds a BS in Pharmacy from the Johannes Gutenberg-University, Germany. He received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996 for his work on drug delivery using nanoparticles. He joined the University of Alberta in 2000, where he is now a Professor in Pharmaceutical Sciences. His research interests are inhalable nanoparticles to treat lung diseases such as lung cancer and tuberculosis. His lab regularly develops and characterises nanoparticles for various inflammatory diseases and cancer. His lab also hosts a unique pencentury device which assists in effectively delivering nanoparticles to the lungs of rodents. He holds a US patent for the delivery of nanoparticles to the lungs. Another major interest area is Biopharmaceutics, and predicting the oral performance of drugs and botanicals.

Prof Löbenberg is a founder and Director of the Drug Development and Innovation Centre at the University of Alberta. The Centre specialises in clinical trial material production, and holds a Health Canada site licence and a drug establishment licence. The Centre has controlled substance licences to synthesise psychedelics in a dedicated chemistry lab. The quality control lab has state-of-the-art analytical instruments and other pharmaceutically relevant performance test instruments. Prof Löbenberg is a former president of the Canadian Society for Pharmaceutical Sciences (2014-2015). He is a member and Vice Chair of the United States Pharmacopeia Dietary Supplement Expert Committee, a Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science, and a member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, and of the Health Canada Scientific Advisory Committee on Opiate Abuse.

Dr. Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua's research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 100 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.

Vinay Parikh is an Associate Professor in the Department of Psychology at Temple University (Philadelphia). He also serves as the Director of Neuroscience Program in Temple's College of Liberal Arts and provides strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh has successfully directed multiple research projects, resulting in notable contributions to the understanding of neural mechanisms underlying cognitive decline in age-related neurodegenerative and psychiatric disorders. His research has also opened new avenues to develop cognition therapies. Dr. Parikh has published more than 90 scientific articles and book chapters in areas of systems and behavioral neuroscience, biological psychiatry, and pharmacology, and serves on several editorial boards of journals. He also regularly serves on scientific advisory and review committees of numerous biomedical research agencies including the National Institute of Health, Alzheimer's Association, and Michael J Fox Foundation.

Dr. Viney Chawla is working as Professor and Principal at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Punjab, India, He has 25 Years of experience in the research, formulation and development of solid lipid nanoparticles, microspheres, nanostructured lipid carriers. Dr. Chawla holds a Ph D Degree in Pharmaceutics and has Published 3 Books, 30 Book Chapters and more than 100 Papers in National/International Journals and is serving as a Reviewer for International Journals of repute. He has guided 40 Post Graduate Projects and his research team consists of 9 Masters and 4 Doctoral Research Scholars.